Re-evaluation Note REV2023-01, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2023-2028

Pest Management Regulatory Agency
26 June 2023
ISSN: 1925-0649 (PDF version)
Catalogue number: H113-5/2023-1E-PDF (PDF version)

Table of contents


The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work planned by Health Canada’s Pest Management Regulatory Agency (PMRA) from 1 April 2023 to 31 March 2028.

This work plan includes the proposed and final decisions published since 1 April 2023, all open re-evaluations and special reviews, as well as new re-evaluations expected to be initiated in this time frame (1 April 2023 to 31 March 2028). This document presents updates to the information last published in Re-evaluation Note REV2022-01, Pest Management Regulatory Agency Re‑evaluation and Special Review Work Plan 2022-2027.

Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the Pest Control Products Act. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.

As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards.

The re-evaluation process is described in Regulatory Directive DIR2016-04, Management of Pesticides Re-evaluation Policy. In addition, a special review may be initiated at any time to address the identified aspect(s) of concern, and a special review is triggered only under certain circumstances. Special reviews differ from re-evaluation in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the PMRA Guidance Document, Approach to Special Reviews of Pesticides.

As required under the Pest Control Products Act, Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations, and new initiations, for active ingredients by visiting the Pesticides section of

This five-year work plan may change in response to workload and emerging issues that require priority action. While this work plan will be updated annually, during the course of the year interested stakeholders can monitor the PMRA’s Public Registry to view the announcement of new re-evaluations and special reviews, as well as the publication of proposed and final decisions.

Part A – Current re-evaluation and special review work plan (Tables 1–3)

The post-market review program workload remains significant and Health Canada acknowledges the need for transformation. In response, Health Canada is developing new and modern business approaches for pesticide evaluations throughout the regulatory life-cycle that will support a sustainable, more efficient and more predictable program that maintains Canada’s high standards of environmental and human health protection and will improve its timely science-based decisions.

During the period, 1 April 2022 to 31 March 2023, Health Canada focussed its resources on the completion of the remaining older pesticide active ingredients registered before 1995. Health Canada introduced the risk based prioritization for the re-evaluation program in 2020 (REV2020-01), and ongoing efforts to streamline the re-evaluation processes for lower priority actives resulted in the completion of majority of lower priority actives. The re-evaluation reviews of several higher priority actives have been delayed due to the demands of focusing resources on completing the re-evaluations of older pesticides, and other priorities including responding to ongoing and increasing litigation, as well as notices of objection, and the scientific complexity associated with certain pesticide reviews. The number of re-evaluation initiations currently required as per the 15-year legislative requirement continues to be high and given the current resource capacity considerations, the backlog is growing.

As part of its Transformation Agenda (PMRA Transformation), Health Canada will continue its work in 2023-2024 to modernize business processes to strengthen human health and environmental protection through a continuous oversight and a proportional effort approach that will focus Health Canada efforts on areas that present the highest risk to health and safety of Canadians and the environment. The new processes will be consulted upon publicly this Fall/Winter 2023/24 to seek the input of experts, partners and stakeholders on the development of these policies. During the post-market review program, when necessary, Health Canada will seek independent scientific advice through Science Advisory Committee (Science Advisory Committee) to better inform its evidence-based decisions.

Part A, Table 1. Targets for consultation and final decisions of special reviews
Active ingredient name Target date of consultationtable 1 note 1
Chlorpropham Q3 (2025–26)
Desmedipham Q4 (2027–28)
Dicamba February 2024
Ethofumesate Q3 (2025–26)
Fosetyl aluminum November 2023
Glufosinate ammonium Q1 (2026–27)
Iodocarb Q3 (2024–25)
  • MCPA (present as acid)
  • MCPA (present as amine salts: diethanolamine, dimethylamine, or mixed amines)
  • MCPA (present as esters)
  • MCPA (present as potassium salt or as sodium salt)
Q3 (2024–25)
Methyl bromide February 2024
Propiconazole Q4 (2025–26)
Pydiflumetofen Q3 (2024–25)
Thiacloprid Q3 (2027–28)
Active ingredient name Target date of final decisiontable 1 note 1
Atrazine Q1 (2024–25)
Chlorothalonil Q1 (2024–25)
Picoxystrobin June 2023
Potassium dimethyldithiocarbamate February 2024
Sodium dimethyldithiocarbamate All end use products Discontinued. Special review closed.
Pentachlorophenol plus related active chlorophenols All end use products Discontinued. Special review closed.
Table 1 Notes
Table 1 Note 1

Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

Return to table 1 note 1 referrer

Part A, Table 2a. Targets for consultation and final re-evaluation decisions
Active ingredient name Re-evaluation category Target datetable 2a note 1 of consultation
Proposed re-evaluation decisions
6-Benzylaminopurine 1 Q4 (2025–26)
Acetamiprid 1 Q4 (2025–26)
Agrobacterium radiobacter strain K84 and K1026 3 August 2023
Azoxystrobin 1 June 2023
Carbon dioxide cluster:
  • Carbon dioxide gas
  • Liquid carbon dioxide
2 October 2024
Clothianidin general re-evaluationtable 2a note2 1 Q3 (2024–25)
Cyprodinil 1 Q4 (2025–26)
D-cis, trans-allethrin 1 Q3 (2025–26)
DEET plus related active toluamides 1 Q1 (2024–25)
Famoxadone 1 Q2 (2024–25)
Fatty Acid cluster:
  • Potassium Salts of Fatty Acids
  • Triethanolamine Salts of Fatty Acids
  • Fatty Acids
  • Ammonium Salt of Fatty Acid
2 Q2 (2024–25)
Fenamidone 1 Q1 (2024–25)
Fluazinam 1 Q4 (2024–25)
Foramsulfuron 3 March 2024
Gibberellins cluster:
  • Gibberellic acid
  • Gibberellins A4A7
3 Q2 (2024–25)
Glufosinate ammonium 1 Q1 (2026–27)
Mecoprop cluster:
  • Mecoprop-P (present as Acid)
  • Mecoprop-P (present as Dimethylamine Salt)
  • Mecoprop-P (present as Potassium Salt)
1 Q2 (2024–25)
Methyl bromide 1 February 2024
Methoxyfenozide 1 Q4 (2026–27)
Naled 3 Q1 (2024–25)
Natamycin 3 December 2023
Nonylphenoxypolyethoxyethanol 3 December 2023
Octenol 3 November 2023
Phorate 2 Q3 (2026–27)
Picolinafen 1 Q3 (2026–27)
Potassium bicarbonate 2 Q2 (2024–25)
S-metolachlor and R-enantiomer 1 February 2024
Sodium chloride 3 June 2023
Spinetoram 1 Q4 (2024–25)
Spinosad 1 Q4 (2024–25)
Sulphur 2 Q4 (2024–25)
Thiamethoxam general re-evaluationtable 2a note2 1 Q3 (2024–25)
Cumulative Health Risk Assessment: N-Methyl Carbamatestable 2a note3 1 Q2 (2025–26)
Cumulative Health Risk Assessment: Organophosphatestable 2a note4 1 January 2024 (publication of work plan)
Active ingredient name Re-evaluation category Target datetable 2a note 1 of final decision
Final re-evaluation decisions
1 or 3-Monomethylol-5,5-dimethyhydantoin and 1,3 bis(hydroxymethyl)-5,5-dimethyhydantoin 1 December 2023
1-Methylcyclopropene 3 September 2023
Abamectin 1 Consultation started 28 February 2023
Bacillus sphaericus 3 October 2023
Bacillus subtilis cluster:
  • Bacillus Subtilis (strain MBI600)
  • Bacillus subtilis (strain QST 713)
3 January 2024
Chondrostereum purpureum (Strain: PFC2139) 3 July 2023
Dodecylguanidine hydrochloride 1 January 2024
Hypochlorite cluster:
  • Available chlorine, present as calcium hypochlorite
  • Available chlorine, present as sodium hypochlorite
  • Sodium hypochlorite
3 August 2023
Flufenacet 1 Q1 (2024–25)
Nucleopolyhedrovirus cluster:
  • Nucleopolyhedrovirus for Douglas-fir tussock moth
  • Neodiprion abietis nucleopolyhedrovirus
3 June 2023
Predacides cluster:
  • Sodium monofluoroacetate
  • Strychnine
1 February 2024
Silicon dioxide cluster:
  • Silica aerogel
  • Silicon dioxide (present as 100% diatomaceous earth) fresh water fossils
3 November 2023
Quizalofop-p-ethyl 1 February 2024
Tebuconazole 1 Q1 (2024–25)
(Z)-9-Tricosene 3 July 2023
Di-n-proyl isocinchomeronate 1 All end use products discontinued. Re-evaluation closed.
Fenbuconazole 1 Registrants notified intent to voluntarily discontinue all end use products. Re-evaluation to be closed once the cancellation process is completed.
Hydramethylnon 1 All end use products discontinued. Re-evaluation closed.
Oxadiazon 1 Registrants notified intent to voluntarily discontinue all end use products. Re-evaluation to be closed once the cancellation process is completed.
Pantoea Agglomerans C9-1 3 All end use products discontinued. Re-evaluation closed.
Table 2a Notes
Table 2a Note 1

Q1 (April–June); Q2 (July–September); Q3 (October–December); Q4 (January–March)

Return to table 2a note 1 referrer

Table 2a Note 2

Cyclical re-evaluations of clothianidin and thiamethoxam were initiated in 2016 to assess their value, as well as human health and environmental risks other than impacts on pollinators and aquatic invertebrates. The assessment of the impacts on pollinators was completed in 2019. Special reviews of clothianidin and thiamethoxam related to aquatic invertebrates were completed in March 2021. Special reviews of clothianidin, thiamethoxam and imidacloprid related to squash bees were completed in February 2022.

Return to table 2a note 2 referrer

Table 2a Note 3

Work plan is published separately (REV2021-01: Project Plan for Cumulative Health Risk Assessment - N-Methyl Carbamates)

Return to table 2a note 3 referrer

Table 2a Note 4

The cumulative risk assessment of the organophosphates: Since the cumulative assessment was initiated, all diazinon products have been voluntarily discontinued by registrants and will expire in December 2023. Therefore, this active ingredient is no longer part of this cumulative assessment.

Return to table 2a note 4 referrer

The re-evaluations of the following active ingredients are in the early part of the re-evaluation process, and Health Canada will provide an updated status in the next work plan to be published in spring 2024:

Part A, Table 2b. Status of other active ingredients (currently in early part of re-evaluation process)
Active ingredient name Current status
1,2-Dibromo-2,4-Dicyanobutane Scoping phase completed
2-(Hydroxymethyl)-2-nitro-1,3-propanediol Scoping phase completed
2-(Thiocyanomethylthio)benzothiazole Scoping phase
10,10'-Oxybis (Phenoxarsine) Scoping phase completed
Acifluorfen, present as sodium salt Scoping phase
Dioxaborinanes cluster:
  • 2,2-(1-Methyltrimethylenedioxy)bis-(4-methyl1,3,2-dioxaborinane)
  • 2,2-Oxybis(4,4,6-trimethyl-1,3,2-dioxaborinane)
Scoping phase
  • Aminopyralid
  • Aminopyralid triisopropanolamine salt
  • Aminopyralid potassium salt
Scoping phase
Antimicrobials cluster:
  • 2,2-Dibromo-3-nitrilopropionamide
  • 2-Methyl-4-isothiazolin-3-one
  • 5-Chloro-2-methyl-4-isothiazolin-3-one
  • 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone
  • Bronopol
  • Methylene bis(thiocyanate)
Scoping phase
Triazinetrione cluster:
  • Available Chlorine, present as Sodium Dichloro-S-Triazinetrione
  • Available Chlorine, present as Trichloro-S-Triazinetrione
  • Trichloro-S-Triazinetrione
Scoping phase
Bensulide Scoping phase completed
Bifenazate Scoping phase completed
Boscalid Scoping phase completed
Bromacil (present in free form, as dimethylamine salt, or as lithium salt) Scoping phase
Carbendazim Scoping phase
Carfentrazone-ethyl Scoping phase
Cyazofamid Scoping phase
Dichlobenil Scoping phase
Daminozide Scoping phase completed
Diflubenzuron Scoping phase
Diphenylamine Scoping phase
Endothal cluster:
  • Endothal
  • Endothal, present as N,N-dimethylalkylamine salt
Scoping phase
Etridiazole Scoping phase
Fish toxicants cluster:
  • 4-Nitro-3-(trifluoromethyl) phenol sodium salt
  • Niclosamide
Scoping phase completed
Fluvalinate-tau Scoping phase
Iodosulfuron-methyl-sodium Scoping phase completed
Ipconazole Scoping phase completed
Mesotrione Scoping phase completed
Metribuzin Scoping phase
Novaluron Scoping phase
Oxyfluorfen Scoping phase
Pinoxaden Scoping phase
Prohexadione calcium Scoping phase
Prothioconazole Scoping phase
Pyrimethanil Scoping phase
Pyraclostrobin Scoping phase completed
Pyrasulfotole Scoping phase
Rodenticide Cluster:
  • Brodifacoum
  • Bromadiolone
  • Bromethalin
  • Chlorophacinone
  • Diphacinone (present in free form or as sodium salt)
  • Warfarin (present in free form or as sodium salt)
  • Zinc phosphide
  • Difethialone
Scoping phase
Spirodiclofen Scoping phase
Spiromesifen Scoping phase
Sulfuryl fluoride Scoping phase
Terbacil Scoping phase
Tetrachlorvinphos Scoping phase completed
Thiacloprid Scoping phase
Topramezone Scoping phase
Triclopyr (present as butoxyethyl ester) Scoping phase
Trifloxystrobin Scoping phase completed
Part A, Table 3. Re-evaluation Initiations between 1 April 2023 and 31 March 2024
Active ingredient Initiation dates
Higher priority actives
(S)-Methoprene To be initiated October 2023
Acequinocyl To be initiated July 2023
Ammonium Bromide To be initiated August 2023
Atrazine (plus related active Triazines) To be initiated December 2023
Bentazon cluster:
  • Bentazon (present as Sodium Salt)
  • Bentazone
To be initiated February 2024
Bispyribac-Sodium (KIH-2023) To be initiated March 2024
Chlorpropham To be initiated January 2024
Clomazone To be initiated September 2023
Didecyldimethylammonium (present as Carbonate and Bicarbonate Salts) To be initiated September 2023
Diuron To be initiated October 2023
EPTC To be initiated February 2024
Fenbutatin Oxide To be initiated December 2023
Metalaxyl cluster:
  • Metalaxyl
  • Metalaxyl-M and S-Isomer
To be initiated January 2024
Napropamide To be initiated February 2024
Oxamyl To be initiated February 2024
Prometryne Plus Related Active Triazines To be initiated August 2023
Pyroxsulam To be initiated January 2024
Rotenone To be initiated January 2024
Sethoxydim To be initiated March 2024
Sulfonyl Ureas cluster:
  • Chlorsulfuron
  • Ethametsulfuron-Methyl
  • Metsulfuron-Methyl
  • Nicosulfuron
  • Rimsulfuron
  • Thifensulfuron-Methyl
To be initiated February 2024
Triallate To be initiated February 2024
Lower priority actives
3-Methyl-2-Cyclohexen-1-One To be initiated June 2023
Cellulose (from Powdered Corn Cobs) To be initiated June 2023
Ferric Sodium Ethylenediaminetetraacetic Acid To be initiated February 2024
German Cockroach Extract To be initiated January 2024
Streptomyces lydicus Strain WYEC108 To be initiated November 2023

Part B – Re-evaluation initiations anticipated between April 2024 and March 2028

The initiation date of the re-evaluation of a particular active ingredient is based on the date of its initial registration, or the date of the last completed re-evaluation.

Part B, Table 1. Future re-evaluation initiations between 1 April 2024 and 31 March 2028

1 April 2024 to 31 March 2025

Active ingredient

  • 1,2-Benzisothiazolin-3-one
  • 2,4-D cluster:
    • 2,4-D (present as Acid)
    • 2,4-D (present as Amine Salts: Dimethylamine Salt, Diethanolamine Salt, or Other Amine Salts)
    • 2,4-D (present as Low Volatile Esters)
    • 2,4-D (present as choline salt)
  • 2-Phenylphenol and Salts cluster:
    • 2-Phenylphenol
    • 2-Phenylphenol (present as Sodium Salt)
    • 2-Phenylphenol (present as Potassium Salt)
  • Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC):
    • N-Alkyl (25% C12, 60% C14, 15% C16) Dimethyl Benzyl Ammonium Chloride
    • N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Chloride
    • N-Alkyl (68% C12, 32% C14) Dimethyl Ethylbenzyl Ammonium Chloride
    • N-Alkyl (5% C12, 60% C14, 30% C16, 5% C18) Dimethyl Benzyl Ammonium Chloride
    • N-Alkyl (67% C12, 25% C14, 7% C16, 1% C18) Dimethyl Benzyl Ammonium Chloride
    • Diisobutylphenoxyethoxyethyl Dimethyl Benzyl Ammonium Chloride
    • N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Saccharinate
    • N-Dialkyl (5% C12, 60% C14, 30% C16, 5% C18) Methyl Benzyl Ammonium Chloride
  • Bacillus thuringiensis cluster:
    • Bacillus thuringiensis Berliner ssp. kurstaki Strain HD-1
    • Bacillus thuringiensis Serotype H-14
    • Bacillus thuringiensis ssp. tenebrionis
  • Beauveria bassiana Strain HF23
  • Bromoxynil
  • Chlorantraniliprole
  • Chlorthal (present as Dimethyl Ester)
  • Cloransulam-Methyl
  • Coniothyrium minitans Strain CON/M/91-08
  • Cyprosulfamide
  • Dicamba (present as Acid, Amine Salt, Ester, Potassium Salt, or Sodium Salt)
  • Didecyl Dimethyl Ammonium Chloride Cluster (DDAC):
    • Didecyl Dimethyl Ammonium Chloride – Other
    • Dioctyl Dimethyl Ammonium Chloride
    • Octyl Decyl Dimethyl Ammonium Chloride
    • Oxydiethylene Bis(Alkyl Dimethyl Ammonium Chloride)
  • Dodine
  • Ethofumesate
  • Flumioxazin
  • Gliocladium catenulatum
  • Glutaraldehyde
  • Imazapyr
  • Maleic Hydrazide
  • MCPA cluster:
    • MCPA (present as Acid)
    • MCPA (present as Amine Salts: Diethanolamine, Dimethylamine, or Mixed Amines)
    • MCPA (present as Esters)
    • MCPA (present as Potassium Salt or as Sodium Salt)
  • Metaldehyde
  • Metarhizium anisopliae Strain F52
  • Mineral Oil
  • Mono- and Di-Potassium Salt of Phosphorous Acid
  • Naphthalene Acetic Acid (present as Ethyl Ester, Sodium Salt, or as Ammonium Salt)
  • Oxirane Derivatives - 50% Minimum
  • Ozone
  • Pendimethalin
  • Picloram cluster:
    • Picloram (present as Potassium Salt)
    • Picloram (present as Acid)
    • Picloram (present as Amine Salts)
  • Propylene Glycol
  • Pyrazon
  • Industrial Uses of Sodium Chlorite and Sodium Chlorate cluster:
    • Sodium Chlorite
    • Sodium Chlorate
  • Spirotetramat
  • Streptomycin
  • Sulfentrazone
  • Tetrakishydroxymethyl phosphonium sulphate
  • Thiencarbazone-Methyl
  • Mandipropamid

1 April 2025 to 31 March 2026

Active ingredient

  • Beauveria Bassiana Strain Gha
  • Bifenthrin
  • Carbathiin
  • Chlormequat Chloride
  • Desmedipham
  • Diazinon
  • Dimethenamid-P
  • Dithiopyr
  • Formetanate Hydrochloride
  • Hexazinone
  • Imazamethabenz-Methyl
  • Lime Sulphur Or Calcium Polysulphide
  • N-Coco-Alkyltrimethylene Diamines present as:
    • Monobenzoate Salt
    • Alkyl-1,3-Propylene Diamine Acetates
    • 1-Alkylamino-3-Aminopropane (Alkyl Groups As Derived From Coconut Oil Fatty Acids)
  • N-Decanol
  • Nosema Locustae Canning (spore of)
  • Oxycarboxin
  • Phenmedipham
  • Propyzamide
  • Pseudomonas Fluorescens A506
  • Tribenuron-Methyl
  • Trifluralin
  • R-(-)-1-Octen-3-Ol
  • Saflufenacil
  • Simazine Plus Related Active Triazines
  • Verticillium Albo-Atrum, Isolate Wcs850

1 April 2026 to 31 March 2027

Active ingredient

  • Diquat
  • Iron (present as FeHEDTA)
  • Tembotrione
  • Naphthalene
  • Animal repellent cluster:
    • Castor Oil
    • Dried Eggs
    • Fish Meal Mixture
    • Fish Oil Mixture
    • Garlic Oil
    • Meat Meal Mixture
    • Wintergreen Oil
  • Pseudomonas Syringae - Strain Esc-10
  • Lactobacillus Casei Strain Lpt-111
  • Lactococcus Lactis Ssp. Lactis Strain Ll64/Csl
  • Lactococcus Lactis Ssp. Lactis Strain Ll102/Csl
  • Lactic Acid
  • Citric Acid
  • Mesosulfuron-Methyl
  • Metrafenone
  • Butoxypolypropylene Glycol
  • Paradichlorobenzene
  • Tefluthrin
  • Flonicamid
  • Acibenzolar-S-Methyl
  • Iodocarb
  • Tralkoxydim
  • Thiabendazole
  • 1,4-Dimethylnaphthalene
  • Diclorprop cluster:
    • Dichlorprop-P
    • Dichlorprop-P (present as Dimethylamine Salt)
    • Dichlorprop P-Isomer (present as 2-Ethylhexyl Ester)
  • Thymol
  • Lactobacillus Rhamnosus Strain Lpt-21
  • Lactococcus Lactis Ssp. Cremoris Strain M11/Csl
  • Imazethapyr
  • Sodium Fluoride
  • 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trimethoxysilsyl quats)
  • 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trihydroxysilyl quats)
  • Diodofon
  • Hexahydro-1,3,5-Tris(2-Hydroxyethyl)-S-Triazine
  • Oxalic Acid Dihydrate
  • D-Limonene
  • Saponins Of Chenopodium Quinoa

1 April 2027 to 31 March 2028

Active ingredient

  • Arsenic Acid
  • Available Bromine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
  • Available Chlorine present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin
  • Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
  • Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5-Ethyl-5-Methylhydantoin and Related Hydantoins
  • Bacillus Firmus I-1582
  • Chromic Acid
  • Clopyralid
  • Copper (present as Basic Copper Carbonate)
  • Copper (present as Copper 8-Quinolinolate)
  • Copper (present as Copper Naphthenate)
  • Creosote
  • Cydia Pomonella Granulovirus (Strain M)
  • Extract of Reynoutria Sachalinensis
  • Fluopicolide
  • Formaldehyde
  • Icaridin
  • Indaziflam
  • Metofluthrin
  • Oriental Mustard Seed Meal
  • Paecilomyces Fumosoroseus Strain Fe 9901
  • Paraformaldehyde
  • Penflufen
  • Penthiopyrad
  • Phoma Macrostoma
  • Propiconazole
  • Trichoderma Asperellum Strain T34
  • Zinc (present as Zinc Oxide)
  • Zinc as Elemental (present as Zinc Naphthenate)

Page details

Date modified: